Sage soars on early postpartum depression data

Sage Therapeutics Inc. (NASDAQ:SAGE) jumped $11.33 (15%) to $86.48 after reporting data from four patients in an exploratory open-label trial of SAGE-547 to treat postpartum depression.

Within 24 hours of treatment with IV SAGE-547, all four patients in the trial achieved statistically significant improvements from baseline as measured by the Hamilton Rating Scale for Depression (HAM-D) (p=0.001). The patients had a mean baseline HAM-D score of 26.5, compared to 1.8 after a 60-hour treatment period. A score above 24 is considered severe, while a score below 7 is symptom-free. ...